IMMUNITYBIO, INC. (IBRX) Free cash flow
- Free cash flow · 12 months (USD): Value $-288.07M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -173.76%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-288.07M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-281.14M − $6.94M ≈ $-288.07M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -173.76% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-288.07M ÷ $165.79M × 100 ≈ -173.76% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-281.14M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.28× | Operating cash flow / net income. Period ending 2026-06-30. $-281.14M ÷ $-992.46M ≈ 0.28× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -281.14M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 6.94M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -288.07M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 165.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -992.46M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-288.07M | (m) | $-281.14M | $6.94M | (m) | $165.79M | (m) | $-992.46M | (m) | (m) | -173.76% | 0.28× |
| 2026-03-31 | $-298.89M | (m) | $-294.39M | $4.50M | (m) | $140.98M | (m) | $-854.64M | (m) | (m) | -212.01% | 0.34× |
| 2025-12-31 | $-308.78M | (m) | $-304.94M | $3.85M | (m) | $113.29M | (m) | $-351.40M | (m) | (m) | -272.56% | 0.87× |
| 2025-09-30 | $-324.76M | (m) | $-319.70M | $5.05M | (m) | $82.56M | (m) | $-348.62M | (m) | (m) | -393.38% | 0.92× |
| 2025-06-30 | $-356.66M | (m) | $-349.56M | $7.11M | (m) | $56.60M | (m) | $-367.09M | (m) | (m) | -630.15% | 0.95× |
| 2025-03-31 | $-376.91M | (m) | $-370.16M | $6.75M | (m) | $31.22M | (m) | $-409.10M | (m) | (m) | -1207.18% | 0.90× |
| 2024-12-31 | $-398.12M | (m) | $-391.24M | $6.89M | (m) | $14.74M | (m) | $-413.56M | (m) | (m) | -2700.06% | 0.95× |
| 2024-09-30 | $-434.10M | (m) | $-421.36M | $12.73M | (m) | $7.33M | (m) | $-587.79M | (m) | (m) | -5920.55% | 0.72× |
| 2024-06-30 | $-425.62M | (m) | $-410.00M | $15.62M | (m) | $1.31M | (m) | $-597.65M | (m) | (m) | -32539.60% | 0.69× |
| 2024-03-31 | $-412.85M | (m) | $-389.43M | $23.42M | (m) | $302.00K | (m) | $-600.96M | (m) | (m) | -136703.97% | 0.65× |
| 2023-12-31 | $-397.34M | (m) | $-366.76M | $30.58M | (m) | $622.00K | (m) | $-583.20M | (m) | (m) | -63881.19% | 0.63× |
| 2023-09-30 | $-383.77M | (m) | $-342.21M | $41.56M | (m) | $556.00K | (m) | $-458.02M | (m) | (m) | -69023.92% | 0.75× |
| 2023-06-30 | $-387.23M | (m) | $-335.41M | $51.82M | (m) | $592.00K | (m) | $-473.38M | (m) | (m) | -65410.47% | 0.71× |
| 2023-03-31 | $-406.13M | (m) | $-346.89M | $59.24M | (m) | $586.00K | (m) | $-430.08M | (m) | (m) | -69305.80% | 0.81× |
| 2022-12-31 | $-415.67M | (m) | $-337.51M | $78.16M | (m) | $240.00K | (m) | $-416.57M | (m) | (m) | -173196.25% | 0.81× |
| 2022-09-30 | $-388.06M | (m) | $-318.42M | $69.63M | (m) | $557.00K | (m) | $-399.61M | (m) | (m) | -69668.76% | 0.80× |
| 2022-06-30 | $-372.27M | (m) | $-310.54M | $61.73M | (m) | $505.00K | (m) | $-376.30M | (m) | (m) | -73716.44% | 0.83× |
| 2022-03-31 | $-342.71M | (m) | $-288.88M | $53.83M | (m) | $809.00K | (m) | $-370.00M | (m) | (m) | -42361.80% | 0.78× |
| 2021-12-31 | $-307.98M | (m) | $-274.42M | $33.56M | (m) | $934.00K | (m) | $-346.79M | (m) | (m) | -32974.52% | 0.79× |
| 2021-09-30 | $-282.85M | (m) | $-260.38M | $22.46M | (m) | $397.00K | (m) | $-325.64M | (m) | (m) | -71245.59% | 0.80× |
| 2021-06-30 | $-241.13M | (m) | $-224.66M | $16.47M | (m) | $482.00K | (m) | $-303.61M | (m) | (m) | -50027.39% | 0.74× |
| 2021-03-31 | $-209.52M | (m) | $-201.09M | $8.44M | (m) | $579.00K | (m) | $-266.76M | (m) | (m) | -36187.05% | 0.75× |
| 2020-12-31 | $-73.09M | (m) | $-70.45M | $2.64M | (m) | $111.00K | (m) | $-92.38M | (m) | (m) | -65848.65% | 0.76× |
| 2020-09-30 | $-65.20M | (m) | $-62.28M | $2.92M | (m) | $99.00K | (m) | $-75.89M | (m) | (m) | -65858.59% | 0.82× |
| 2020-06-30 | $-62.21M | (m) | $-60.57M | $1.63M | (m) | $43.00K | (m) | $-69.70M | (m) | (m) | -144667.44% | 0.87× |
| 2020-03-31 | $-63.10M | (m) | $-60.88M | $2.22M | (m) | $59.00K | (m) | $-66.29M | (m) | (m) | -106955.93% | 0.92× |
| 2019-12-31 | $-65.54M | (m) | $-61.36M | $4.18M | (m) | $43.00K | (m) | $-65.79M | (m) | (m) | -152427.91% | 0.93× |
| 2019-09-30 | $-66.06M | (m) | $-60.51M | $5.55M | (m) | $41.00K | (m) | $-67.49M | (m) | (m) | -161114.63% | 0.90× |
| 2019-06-30 | $-70.31M | (m) | $-61.51M | $8.80M | (m) | $60.00K | (m) | $-75.54M | (m) | (m) | -117176.67% | 0.81× |
| 2019-03-31 | $-71.25M | (m) | $-60.95M | $10.30M | (m) | $47.00K | (m) | $-86.59M | (m) | (m) | -151600.00% | 0.70× |
| 2018-12-31 | $-76.48M | (m) | $-63.38M | $13.10M | (m) | $47.00K | (m) | $-96.23M | (m) | (m) | -162729.79% | 0.66× |
| 2018-09-30 | $-85.48M | (m) | $-62.99M | $22.49M | (m) | $52.00K | (m) | $-103.37M | (m) | (m) | -164380.77% | 0.61× |
| 2018-06-30 | $-85.09M | (m) | $-55.55M | $29.54M | (m) | $29.00K | (m) | $-103.71M | (m) | (m) | -293427.59% | 0.54× |
| 2018-03-31 | $-89.44M | (m) | $-54.23M | $35.21M | (m) | $39.00K | (m) | $-99.43M | (m) | (m) | -229338.46% | 0.55× |
| 2017-12-31 | $-83.59M | (m) | $-48.78M | $34.81M | (m) | $45.00K | (m) | $-96.42M | (m) | (m) | -185766.67% | 0.51× |
| 2017-09-30 | $-70.63M | (m) | $-45.89M | $24.74M | (m) | $47.00K | (m) | $-96.17M | (m) | (m) | -150282.98% | 0.48× |
| 2017-06-30 | $-63.55M | (m) | $-46.44M | $17.10M | (m) | $51.00K | (m) | $-104.10M | (m) | (m) | -124598.04% | 0.45× |
| 2017-03-31 | $-49.80M | (m) | $-39.79M | $10.00M | (m) | $49.00K | (m) | $-114.65M | (m) | (m) | -101624.49% | 0.35× |
| 2016-12-31 | $-45.15M | (m) | $-38.59M | $6.56M | (m) | $44.00K | (m) | $-120.81M | (m) | (m) | -102620.45% | 0.32× |
| 2016-09-30 | $-44.94M | (m) | $-38.78M | $6.16M | (m) | $44.00K | (m) | $-123.39M | (m) | (m) | -102138.64% | 0.31× |
| 2016-06-30 | $-36.51M | (m) | $-32.30M | $4.21M | (m) | $43.00K | (m) | $-137.81M | (m) | (m) | -84911.63% | 0.23× |
| 2016-03-31 | $-30.06M | (m) | $-26.79M | $3.27M | (m) | $122.00K | (m) | $-234.68M | (m) | (m) | -24638.52% | 0.11× |
| 2015-12-31 | $-27.55M | (m) | $-25.30M | $2.24M | (m) | $236.00K | (m) | $-236.88M | (m) | (m) | -11672.03% | 0.11× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $-12.75M | (m) | (m) | $475.00K | (m) | $-37.95M | (m) | (m) | (m) | 0.34× |
| 2014-12-31 | $-5.65M | (m) | $-5.42M | $235.00K | (m) | $641.00K | (m) | $-6.18M | (m) | (m) | -881.90% | 0.88× |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-671.00K | (m) | $-668.00K | $3.00K | (m) | $600.00K | (m) | $-2.05M | (m) | (m) | -111.83% | 0.33× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |